
**What is claimed is:**

1. A composition comprising:

(a) the compound PAC-1:




(PAC-1);

(b) a second active agent, which agent is an inhibitor of the BRAF enzyme having a mutation, wherein the second active agent is:

dabrafenib and the concentration of dabrafenib is about 0.5 μM to about 50 μM;

encorafenib and the concentration of encorafenib is about 25 nM to about 1 mM; or

vemurafenib and the concentration of vemurafenib is about 0.5 μM to about 30 μM; and

(c) a pharmaceutically acceptable diluent, excipient, or carrier;

wherein the concentration of PAC-1 is about 4 μM to about 12 μM.

2. The composition of claim 1 wherein vemurafenib is an inhibitor of the BRAF enzyme that has the V600E or the V600K mutation.

3. The composition of claim 1 or 2 wherein the composition further comprises a MEK inhibitor.

4. The composition of claim 1 wherein the carrier comprises water, a buffer, a sugar, a cellulose, a cyclodextrin, or a combination thereof.

5. The composition of claim 1 wherein the second active agent is:

dabrafenib and the concentration of dabrafenib is about 0.5 μM to about 10 μM; or

encorafenib and-the concentration of encorafenib is about 50 nM.